title: The fixed combination efficacy assessment in patients with secondary neovascular glaucoma and diabetes mellitus.
abstract: OBJECTIVE
  To assess IOP-lowering efficacy of bimatoprost/timolol fixed combination (Ganfort®) in patients with diabetes mellitus (DM) and uncontrolled secondary neovascular glaucoma (NG).
  
  
  METHODS
  Fifty patients (51 eyes) with uncontrolled secondary neovascular glaucoma and diabetes mellitus were enrolled in the study. All patients with an uncontrolled IOP have been proposed to switch current IOP-lowering therapy to Ganfort®. In case target IOP level was not reached filtration surgery was recommended. Ganfort® administration - once a day in the morning.
  
  
  RESULTS
  IOP-lowering has been observed in all patients when switched to Ganfort®. Mean IOP level was almost 3-x lower versus baseline in 72.5% of patients (37 eyes). The patients achieved target IOP of 15-17 mmHg. As a result, no surgical intervention was required. Significant IOP-lowering has been observed in another group of patients (14 eyes, 27.5 %) nevertheless due to glaucoma progression, these patients are still subjected to surgical treatment.
  
  
  CONCLUSIONS
  IOP-lowering fixed combination Ganfort® (Allergan) can be used in patients with secondary neovascular glaucoma and diabetes mellitus as a drug of choice to control the IOP level. Even in cases when target IOP is not achieved, Ganfort® can be administered in pre-operative period and helps to reduce postoperative complications.
authors.affiliation: Dmitry Ulyanov Street 11, Office 223, Department of Ophthalmology Endocrinology Research Center, Moscow, 117036, Russia. glas1966@rambler.ru.
authors.forename: D V
authors.initials: DV
authors.lastname: Lipatov
authors.forename: T A
authors.initials: TA
authors.lastname: Chistyakov
authors.forename: A G
authors.initials: AG
authors.lastname: Kuzmin
authors.forename: A A
authors.initials: AA
authors.lastname: Tolkacheva
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000577:Amides / Q000009:adverse effects / Q000627:therapeutic use*; D003008:Cloprostenol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003925:Diabetic Angiopathies / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D004338:Drug Combinations; D057915:Drug Substitution; D005260:Female; D015355:Glaucoma, Neovascular / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D013999:Timolol / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D000577:Amides; D004338:Drug Combinations; C571755:Ganfort; D003008:Cloprostenol; D013999:Timolol